Class: Urinary Antispasmodic
Dosage Forms. Tablet: 5 mg, 10 mg
Common FDA Label Indication, Dosing, and Titration.
1. Overactive bladder: 5 mg po daily, may titrate to 10 mg po daily
Off-Label Uses. None
MOA. Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion.
Drug Characteristics: Solifenacin
Medication Safety Issues: Solifenacin
Drug Interactions: Solifenacin
Adverse Reactions: Solifenacin
Efficacy Monitoring Parameters. Resolution of clinical signs of incontinence, urinary urgency and frequency.
Toxicity Monitoring Parameters. Seek medical attention for severe anticholinergic effects (severe dry mouth, cognitive impairment, constipation, vision changes). Monitor vital signs.
Key Patient Counseling Points. This drug may cause anticholinergic effects including constipation, urinary retention, blurred vision, dyspepsia, or xerostomia. Heat prostration (due to decreased sweating) can occur when used in a hot environment.
Clinical Pearls. Patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug’s effects have been determined. May cause decline in cognitive function, especially in the elderly.